Ambros Therapeutics

Ambros Therapeutics, headquartered in Irvine, California, is a clinical-stage biotechnology company focused on developing innovative and transformative medicines for diseases with high unmet medical need. Its lead investigational program targets complex regional pain syndrome type 1 (CRPS-1), a devastating rare disease causing severe, unrelenting pain following trauma to the bone, with no FDA-approved treatments currently available. The company's approach centers on neridronate, a differentiated bisphosphonate with established efficacy in bone disease, whose unique structure and binding characteristics balance safety and efficacy versus other bisphosphonates. Ambros is running the CRPS-RISE Phase 3 pivotal trial evaluating neridronate in CRPS-1 patients in the United States, representing a first-in-class approach to the disease. The company launched publicly in December 2025 backed by a $125M Series A co-led by RA Capital Management and Patient Square Capital, and is an Arkin Bio portfolio company.